Recently, Arely and colleagues switched to an anti-SIRPα monoclonal antibody in the study and blocked this mechanism to enhance the tumor phagocytosis of macrophages; the effect was better than that in previous experiments (78), and another research team found the anti-human SIRPα antibody, KWAR23, could significantly promote the anti-tumor activity of neutrophils and TAMs when it was in combination with the tumor-opsonizing antibody rituximab (79) (Figure 3B). This evidence concerns the gene SIRPA and neoplasm.